Historical perspective on the use of animal bioassays to predict carcinogenicity: Evolution in design and recognition of utility

被引:18
作者
Beyer, L. A. [1 ]
Beck, B. D. [1 ]
Lewandowski, T. A. [2 ,3 ]
机构
[1] Gradient Corp, Cambridge, MA 02138 USA
[2] Gradient Corp, Seattle, WA 98101 USA
[3] CUNY, CUNY Brooklyn Coll, Dept Hlth & Nutr Sci, Brooklyn, NY 11210 USA
关键词
Animal bioassays; animal testing; cancer bioassays; chronic animal testing; historical analysis; US public health service; HUMAN CANCER-RISK; VINYL-CHLORIDE; IDENTIFYING CARCINOGENS; CHEMICAL CARCINOGENESIS; INHALATION EXPOSURE; CHRONIC TOXICITY; IARC-MONOGRAPHS; DOSE SELECTION; RODENT CARCINOGENICITY; INDUSTRIAL-CHEMICALS;
D O I
10.3109/10408444.2010.541222
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
The animal testing protocols used today to evaluate the carcinogenicity of chemicals are very different from those used in the earlier part of the 20th century. To explore how cancer bioassays have changed over time, we surveyed the literature discussing test design and interpretation from the 1930s to the present. We also analyzed compendia of bioassays published by the US Public Health Service (US PHS) from 1938 to 1978, and evaluated the data to understand the evolution of testing methodology (e. g., animals used, test duration) and the types of chemicals being studied. The cancer bioassay evolved in several stages. At the beginning of the 20th century, animal bioassays were primarily used to re-create known human diseases, whereas in the 1940s to 1960s, animal bioassays were largely used to evaluate the safety of chemicals in foods, drugs, and cosmetics. Beginning in the late 1960s and 1970s, chemicals primarily associated with occupational or environmental exposures were also evaluated. Testing strategies now emphasize a suite of tests including multiple in vitro tests and both short-term and long-term animal tests. The objectives of testing are broader, too, with test goals encompassing information regarding mode of action and other parameters aimed at evaluating potential species differences (e. g., in toxicokinetics) and their relevance for evaluating human risks. It is important to consider this evolution when evaluating the testing methodology and scientific conclusions in earlier eras. As toxicology continues to develop, testing methods will continue to change in concert with increased knowledge and understanding.
引用
收藏
页码:321 / 338
页数:18
相关论文
共 164 条
[1]   CARCINOGEN RISK ASSESSMENT IN THE US ENVIRONMENTAL-PROTECTION-AGENCY [J].
ALBERT, RE .
CRITICAL REVIEWS IN TOXICOLOGY, 1994, 24 (01) :75-85
[2]   CHEMICAL CARCINOGENESIS - TOO MANY RODENT CARCINOGENS [J].
AMES, BN ;
GOLD, LS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (19) :7772-7776
[3]   A GENERAL SCHEME FOR THE INCORPORATION OF PHARMACOKINETICS IN LOW-DOSE RISK-ESTIMATION FOR CHEMICAL CARCINOGENESIS - EXAMPLE - VINYL-CHLORIDE [J].
ANDERSON, MW ;
HOEL, DG ;
KAPLAN, NL .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1980, 55 (01) :154-161
[4]  
[Anonymous], FED REG
[5]  
[Anonymous], 2009, SCI DEC ADV RISK ASS, DOI DOI 10.17226/12209
[6]  
[Anonymous], 1991, IARC MON EV CARC RIS, V53
[7]  
[Anonymous], RISK ASS FED GOV MAN
[8]  
[Anonymous], 1978, FED REGISTER, V43, P59986
[9]  
[Anonymous], 2007, Toxicity testing in the 21st century : a vision and a strategy
[10]  
[Anonymous], 1997, PRINCIPLES SELECTION